Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,734,000 | 217,000 | 146,000 | 188,000 | 196,000 |
| Receivables | 1,531,000 | 1,828,000 | 1,608,000 | 1,548,000 | 1,472,000 |
| Inventories | 1,351,000 | 1,579,000 | 1,166,000 | 1,078,000 | 955,000 |
| Income taxes - deferred | N/A | N/A | N/A | N/A | 75,000 |
| Other current assets | 1,884,000 | 880,000 | 922,000 | 942,000 | 541,000 |
| TOTAL | $6,694,000 | $4,699,000 | $4,003,000 | $3,822,000 | $3,239,000 |
| Non-Current Assets | |||||
| PPE Net | 2,084,000 | 2,079,000 | 1,782,000 | 1,697,000 | 1,630,000 |
| Intangibles | 15,868,000 | 18,062,000 | 14,283,000 | 12,835,000 | 12,561,000 |
| Other Non-Current Assets | 6,131,000 | 5,725,000 | 932,000 | 688,000 | 666,000 |
| TOTAL | $24,083,000 | $25,866,000 | $16,997,000 | $15,220,000 | $14,857,000 |
| Total Assets | $30,777,000 | $30,565,000 | $20,999,000 | $19,042,000 | $18,096,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 13,000 | 1,416,000 | N/A | 1,801,000 | 64,000 |
| Accounts payable and accrued liabilities | 513,000 | 542,000 | 349,000 | 530,000 | 447,000 |
| Accrued Expenses | 2,197,000 | 2,109,000 | 2,246,000 | 2,456,000 | 2,312,000 |
| Other current liabilities | 958,000 | 800,000 | 412,000 | 867,000 | 764,000 |
| TOTAL | $3,681,000 | $4,866,000 | $5,260,000 | $5,654,000 | $3,587,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 9,130,000 | 8,592,000 | 4,803,000 | 3,815,000 | 5,420,000 |
| Other Non-Current Liabilities | 2,309,000 | 2,635,000 | 1,882,000 | 2,370,000 | 2,338,000 |
| TOTAL | $11,769,000 | $11,822,000 | $7,013,000 | $6,376,000 | $7,776,000 |
| Total Liabilities | $15,451,000 | $16,688,000 | $12,273,000 | $12,030,000 | $11,363,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,417,166 | 1,396,195 | 1,385,962 | 1,374,911 | 1,363,489 |
| Common Shares | 17,000 | 16,000 | 16,000 | 16,000 | 16,000 |
| Retained earnings | -2,378,000 | -2,253,000 | -6,953,000 | -8,390,000 | -8,581,000 |
| Other shareholders' equity | 206,000 | 270,000 | 34,000 | -58,000 | 1,000 |
| TOTAL | $15,326,000 | $13,877,000 | $8,726,000 | $7,012,000 | $6,733,000 |
| Total Liabilities And Equity | $30,777,000 | $30,565,000 | $20,999,000 | $19,042,000 | $18,096,000 |